Genetic assessment of cardiovascular risk factors in the Greek Cypriot population

Thrombosis Research

Volumn 112, Issue 3, 2003, Pages 143-146

  Koumas, Laura ^a   Costeas, Paul A ^a   Papaloizou, Andri ^a   Giantsiou Kyriakou, Alina ^a  

^a Karaiskakio Foundation   (Cyprus)

Author keywords

Cardiovascular risk factors; Greek Cypriot; Thrombophilia

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN E; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5 LEIDEN; DIHYDROFOLATE REDUCTASE; FIBRINOGEN; GLYCOPROTEIN IIIA; PLASMINOGEN ACTIVATOR INHIBITOR; PROTHROMBIN;

ARTICLE; BEHAVIOR; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DNA POLYMORPHISM; ENVIRONMENTAL FACTOR; FAMILY HISTORY; FEMALE; GENETIC ANALYSIS; GENETIC PREDISPOSITION; GENETIC RISK; GREECE; HUMAN; IMMOBILIZATION; LIFESTYLE; MALE; ORAL CONTRACEPTION; POPULATION RESEARCH; PREGNANCY; PRIORITY JOURNAL; SMOKING; THROMBOPHILIA; THROMBOSIS;

EID: 1042275520     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2003.12.012     Document Type: Article

References (22)

1. Milewicz D.M., Seidman C.E. Genetics of cardiovascular disease. Circulation. 102:2000;IV103-IV111.
2. Endler G., Mannhalter C. Polymorphisms in coagulation factor genes and their impact on arterial and venous thrombosis. Clin. Chim. Acta. 330:2003;31-55.
3. Angelopoulou K., Nicolaides A., Constantinou Deltas C. Prevalence of genetic mutations that predispose to thrombophilia in a Greek Cypriot population. Clin. Appl. Thromb. Hemost. 6:2000;104-107.
4. Xenophontos S.L., Hadjivassiliou M., Ayrton N., Karagrigoriou A., Pantzaris M., Nicolaides A.N.et al. Spectrum and prevalence of prothrombotic single nucleotide polymorphism profiles in the Greek Cypriot population. Int. Angiol. 21:2002;322-329.
5. Pecheniuk N.M., Morris C.P., Walsh T.P., Marsh N.A. The factor V HR2 haplotype: prevalence and association of the A4070G and A6755G polymorphisms. Blood Coagul. Fibrinolysis. 12:2001;201-206.
6. Antoniadi T., Hatzis T., Kroupis C., Economou-Petersen E., Petersen M.B. Prevalence of factor V Leiden, prothrombin G20210A, and MTHFR C677T mutations in a Greek population of blood donors. Am. J. Hematol. 61:1999;265-267.
7. Coen D., Zadro R., Honovic L., Banfic L., Stavljenic Rukavina A. Prevalence and association of the factor V Leiden and prothrombin G20210A in healthy subjects and patients with venous thromboembolism. Croat. Med. J. 42:2001;488-492.
8. Tosetto A., Missiaglia E., Frezzato M., Rodeghiero F. The VITA project: prothrombin G20210A mutation and venous thromboembolism in the general population. Thromb. Haemost. 82:1999;1395-1398.
9. Vargas M., Soto I., Pinto C.R., Urgelles M.F., Batalla A., Rodriguez-Reguero J.et al. The prothrombin 20210A allele and the factor V Leiden are associated with venous thrombosis but not with early coronary artery disease. Blood Coagul. Fibrinolysis. 10:1999;39-41.
10. Jastrzebska M., Goracy I., Naruszewicz M. Relationships between fibrinogen, plasminogen activator inhibitor-1, and their gene polymorphisms in current smokers with essential hypertension. Thromb. Res. 110:2003;339-344.
11. Rees D.C., Cox M., Clegg J.B. World distribution of factor V Leiden. Lancet. 346:1995;1133-1134.
12. Renner W., Koppel H., Hoffmann C., Schallmoser K., Stanger O., Toplak H.et al. Prothrombin G20210A, factor V Leiden, and factor XIII Val34Leu: common mutations of blood coagulation factors and deep vein thrombosis in Austria. Thromb. Res. 99:2000;35-39.
13. Wartiovaara U., Perola M., Mikkola H., Totterman K., Savolainen V., Penttila A.et al. Association of FXIII Val34Leu with decreased risk of myocardial infarction in Finnish males. Atherosclerosis. 142:1999;295-300.
14. Zhang L., Stradmann-Bellinghausen B., Schneider P.M., Rittner C. Genetic polymorphisms of the A and B subunits of coagulation factor XIII in the Chinese population. Exp. Clin. Immunogenet. 10:1993;137-140.
15. Papazoglou D., Exiara T., Speletas M., Panagopoulos I., Maltezos E. Prevalence of Hemochromatosis Gene (HFE) Mutations in Greece. Acta Haematol. 109:2003;137-140.
16. MacLean R.M., Feeney G.P., Bowley S.J., Bowen D.J., Worwood M., Collins P.W. Factor V Leiden and the common haemochromatosis mutation HFE C282Y: is there an association in familial venous thromboembolic disease? Br. J. Haematol. 107:1999;210-212.
17. Brown K., Luddington R., Taylor S.A., Lillicrap D.P., Baglin T.P. Risk of venous thromboembolism associated with the common hereditary haemochromatosis Hfe gene (C282Y) mutation. Br. J. Haematol. 105:1999;95-97.
18. Franco R.F., Zago M.A., Trip M.D., Ten Cate H., van den Ende A., Prins M.H.et al. Prevalence of hereditary haemochromatosis in premature atherosclerotic vascular disease. Br. J. Haematol. 102:1998;1172-1175.
19. Castillo S., Tejedor D., Mozas P., Reyes G., Civeira F., Alonso R.et al. The apolipoprotein B R3500Q gene mutation in Spanish subjects with a clinical diagnosis of familial hypercholesterolemia. Atherosclerosis. 165:2002;127-135.
20. Horvath A., Ganev V. The mutation APOB-100 R3500Q in Eastern Europe. Atherosclerosis. 156:2001;241-242.
21. Lahoz C., Schaefer E.J., Cupples L.A., Wilson P.W., Levy D., Osgood D.et al. Apolipoprotein E genotype and cardiovascular disease in the Framingham Heart Study. Atherosclerosis. 154:2001;529-537.
22. Eichner J.E., Dunn S.T., Perveen G., Thompson D.M., Stewart K.E., Stroehla B.C. Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. Am. J. Epidemiol. 155:2002;487-495.